RT Journal Article
SR Electronic
T1 Omicron-specific cytotoxic T-cell responses are boosted following a third dose of mRNA COVID-19 vaccine in anti-CD20-treated multiple sclerosis patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.20.21268128
DO 10.1101/2021.12.20.21268128
A1 Natacha Madelon
A1 Nelli Heikkilä
A1 Irène Sabater Royo
A1 Paola Fontannaz
A1 Gautier Breville
A1 Kim Lauper
A1 Rachel Goldstein
A1 Alba Grifoni
A1 Alessandro Sette
A1 Claire-Anne Siegrist
A1 Axel Finckh
A1 Patrice H. Lalive
A1 Arnaud M. Didierlaurent
A1 Christiane S. Eberhardt
YR 2021
UL http://medrxiv.org/content/early/2021/12/21/2021.12.20.21268128.abstract
AB Importance The SARS-CoV-2 variant Omicron escapes neutralizing antibody responses elicited after COVID-19 vaccination, while T-cell responses might be better conserved. It is crucial to assess how a third dose of vaccination modifies these responses, particularly for immunocompromised patients with readily impaired antibody responses.Objective To determine T-cell responses to the Spike (S)-protein of Omicron in anti-CD20 treated patients before and after their third mRNA COVID-19 vaccinationDesign Prospective observational monocentric studySetting Conducted since March 2021 at the University Hospital GenevaParticipants Twenty adults with multiple sclerosis on anti-CD20 treatment (ocrelizumab) who received their third dose of mRNA COVID-19 vaccine 6 to 7 months after their second vaccination. Intervention: Blood sampling before and one month after the third vaccine doseMain outcomes and measures Quantification of CD4 and CD8 (cytotoxic) T cells specific for SARS-CoV-2 S-protein of vaccine strain, Delta and Omicron variants, using activation marker induced assay (AIM) and comparing frequencies before and after the third vaccine dose.Results S-specific CD4 and CD8 T-cell memory against all variants was maintained in around half of the patients six months after their second vaccination, albeit at lower frequencies against Delta and Omicron variants. A third dose enhanced the number of responders to all variants and significantly increased CD8 T-cell responses. The frequencies of T cells specific to Omicron and Delta remained lower than those specific to the vaccine strain after the boost.Conclusion and relevance Vaccinated MS patients on anti-CD20 treatment show robust T-cell responses that recognize S from the circulating Delta and Omicron variants. Response rates increased after the third dose, demonstrating that a booster dose might improve cytotoxic T-cell mediated protection against severe disease in patients with low humoral response. The clinical relevance of the reduced frequencies of T cells specific to Omicron will need to be monitored in the future.Question Are T-cell responses to Omicron variant conserved in anti-CD20 treated MS patients after COVID-19 mRNA vaccination?Findings Omicron Spike-specific CD4 and CD8 T cells were detectable in around half of twenty patients six months after the second COVID-19 vaccine dose, and cytotoxic T-cell responses increased following the third dose. Frequencies of T cells specific against the S-protein of Delta and Omicron were lower compared to the vaccine strain, both before and after boost.Meaning In anti-CD20-treated MS patients the vaccine-induced T-cell responses are little affected by the mutations carried by Omicron, and a third vaccine dose improves cytotoxic T-cell responses.Competing Interest StatementA.S. is a consultant for Gritstone Bio, Flow Pharma, Arcturus Therapeutics, ImmunoScape, CellCarta, Avalia, Moderna, Fortress and Repertoire. A.D. is a consultant for Speranza. LJI has filed for patent protection for various aspects of T cell epitope and vaccine design work. All of the other authors declare no competing interests.Funding StatementThis work was supported by the HUG private Foundation (CSE, CAS, AD) and by the Giorgi-Cavaglieri foundation (AD). This work was additionally funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00016 and 75N9301900065 to A.S.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This prospective observational study has been carried out since March 2021 at the Geneva University Hospitals, Switzerland, according to the principles of Good Clinical Practice and was approved by the Geneva Cantonal Ethics Commission (2021-00430)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors